Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines

A method of treating an individual afflicted with an inflammatory disorder mediated by LTB4 comprising administering to said individual an effective amount of at least one compound according to Formula I:

• 12
• wherein:
• R1 is —(C1-C7)hydrocarbyl or —(C2-C6)heteroalkyl;
• R2 is selected from the group consisting of —H, and —(C1-C7)hydrocarbyl;
• wherein R1 and R2 may combine to form a carbocyclic or heterocyclic 5- or 6-membered ring;
• R3 is independently selected from the group consisting of —O(C1-C6)alkyl, —OH, —O-acyl, —SH, —S(C1-C3)alkyl, —NH2, —NH(C1-C6)alkyl, —N((C1-C6)alkyl)2, —NH-acyl, —NO2 and halogen;
• n is 1, 2 or 3;
• R4 and R5 are independently selected from the group consisting of —O(C1-C6)alkyl, —OH, O-acyl, —SH, —S(C1-C3)alkyl, —NH2, NH-acyl and halogen;
• wherein, R4 and R5 may combine to form a 5, 6 or 7-membered heterocyclic ring;
• and
• wherein, compounds according to formula I are (R)-enantiomers substantially free of the corresponding (S)-enantiomers, with respect to the absolute conformation at the 5-position of the benzodiazepine ring;
• or a pharmaceutically-acceptable salt of such a compound.